Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They had a 10 for 1 reverse split a couple of years ago, desperate to state listed, didn't make it. Delisted and has augured in here in penny land. They are trying prayer circles.
at least something is happening... hopefully they can reverse this downward skid!
That's my guess...
Co announced yesterday that it is exploring all strategic options to maximize the value of its assets and has retained Jefferies LLC as exclusive financial advisor to assist it with reviewing and structuring potential strategic transactions. The Company does not intend to comment further on this process unless and until a definitive agreement has been reached.
well said. TNGN has potential, but patience is needed...
I would agree except for the fact that they will probably do a R/s at 1:50, meaning their A/S drops to 200M, with an O/S of around 500,000. I haven't looked through the filings, but if they hadn't bumped up their A/S I'm not sure if they would have had enough shares to cover preferreds, etc... This of course does not block diluting in the future and the percentages remain the same. What will remain to be seen is how they engage in the dilution. Mostly it will likely be used for debt financing. Depending on terms, that might not be so horrid-possibly relatively neutral since they will be adding value to the company, rather than rewarding the CEO or other insider. More exciting would be if they got some increased institutional/VC interest with the higher share price (should jump to around $3 PPS). It is possible that the R/S would be a catalyst for increased share price action and if they were to raise cash by selling smartly into the market it could actually drive share price up.
IMO, this isn't like some pennies looking to just use the market as an ATM, they ARE burning cash to develop a product that will be a good target for takeover, but that requires capital. I don't this they are going to go through the R/S, dilute, R/S cycle endlessly.
GLTA!
Not much to figure out. A company does not raise the A/S from 750m to 10B unless they plan on issuing somwhere between 750m and 10B shares - read the filings - they are diluting the hell out of it and, unfortunately, they have quite a ways to go....I have seen this so many times before - they will dilute to stay alive while the s/p goes sub-penny - hoping to be able to turn the corner and R/S in the future. I read a SA article that called TNGN "dilution hell with no way out..." (google it)
agree, and totally confused on this one. Dumb enough to average down if I could figure out what the hell is going on.
Holding and praying now
I came across tngn in an article a coworker showed me two weeks ago, and bought $1k worth in an ah f-it moment... hopefully my gamble pays off :]
any predictions on when we'll get a PR or update on current progress? I read the recent QR but didn't gather what their goals are other than obtaining more financing before the end of 2014
not adding, just holding and waiting
It wasn't that long ago there was a 10 for 1 reverse split and really I'd have to have the pps hit somewhere around $17 to break even....something is hinky .... I bought around the time an executive from the company bought...pre split up near $3 dollars...thinking like many investors that this was a good sign...perhaps it was something else ....
TNGN could use a featured story on 60 minutes or similar major news outlet coverage... :D
Yeh, approved share is different than Outstanding shares....could be leverage as they seek renewed funding from BP
The 10 b shares are not close to being exercises. The actual outstanding is sub 150m
And here is result of vote(approval)
www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9812605
That's what I can't find. Sold a while back when it was above $1. Thought about jumping back in at this price...but not if AS is 10B. Yikes! Thanks
Dear Celgene, please buy us for $2 share before 2015. Thank you
The A/S was increased to 10B several months ago, but I can't seem to find the SEC filing to document this. That, and their huge debt, is why I sold out entirely yesterday.
Where did you get 10 billion from?
TNGN is another high risk high reward biotech worth gambling on IMO....
This is just about as good as news as we can expect from Tengion.
NEWS out!!
Tengion Provides Clinical Update and Reports Second Quarter 2014 Financial Results
BY GlobeNewswire
— 12:31 PM ET 08/13/2014
WINSTON-SALEM, N.C., Aug. 13, 2014 (GLOBE NEWSWIRE) -- Tengion, Inc. (TNGN) , a leader in regenerative medicine, today reported key clinical data along with financial and operating results for the quarter ended June 30, 2014.
"Today, we are pleased to announce encouraging six-month interim data for the first five patients implanted in the Phase 1 clinical trial of our Neo-Kidney Augment (NKA) cellular therapy being conducted in Sweden. We believe these early trends support the promising potential of this cellular therapy, and based on our review of the six-month data for measurements of kidney function, including hemoglobin, serum creatinine, calculated estimated Glomerular Filtration Rate (eGFR), magnetic resonance imaging (MRI), and renal scintigraphy, we believe clinical investigation should continue aggressively. We look forward to reporting full data for this trial and our U.S. trial after completing patient enrollment in both trials, which we expect in the first half of 2015. Based on early investigator experience, we have modified a number of trial design elements, including inclusion and exclusion criteria for patient qualification to participate in the trials, and are exploring the use of a minimally invasive implantation method in the future in order to improve our initial rate of patient enrollment, which has been slower than anticipated," commented John L. Miclot, President and Chief Executive Officer of Tengion (TNGN). "We remain focused on our mission of providing life-changing advantages for patients in need of improvements over the current standards of care using our proprietary platform enabling the generation of native-like organs and tissues."
Neo-Kidney Augment™ Cellular Therapy Clinical Update
Tengion (TNGN) is currently conducting Phase 1 clinical trials for its NKA cellular therapy in Sweden and the United States and expects to enroll up to 15 and 12 patients, respectively, in these two trials. Both Phase 1 trials are designed to evaluate the safety and delivery of an active regenerative dose of NKA cellular therapy, including two years of follow-up, in patients with chronic kidney disease (CKD). The Company expects to complete patient enrollment in these two clinical trials during the first half of 2015.
Today, the Company announced six-month interim data for the first five patients with advanced CKD implanted in the Phase 1 clinical trial being conducted at the Karolinska Institute in Stockholm, Sweden. NKA cellular therapy was successfully implanted into one kidney of each patient. Four surgical procedure-related serious adverse events were recorded in this trial. None of these events were determined to be related to the NKA material and none caused the patients to discontinue the trial or the Data Safety Monitoring Board to stop the trial. None of the reported adverse events were kidney-related.
Neo-Urinary Conduit™ Clinical Program Update
Tengion (TNGN) has completed enrollment in its ongoing Phase 1 clinical trial for the Neo-Urinary Conduit. Bladder cancer patients were enrolled in the trial to assess the safety and preliminary efficacy of the Neo-Urinary Conduit, as well as to translate the surgical implantation procedure utilized in preclinical studies. The Company is working with key opinion leaders on future development plans for the Neo-Urinary Conduit, and will seek to execute a strategic or financial transaction to provide targeted funding for future development of the Neo-Urinary Conduit. In the absence of such funding, the Company does not plan to continue independent development of the Neo-Urinary Conduit program.
Second Quarter 2014 and the Six Months Ended 2014 Financial Results
For the quarter ended June 30, 2014, the Company reported an adjusted net loss of $6.5 million, or $0.30 per basic and diluted common share, compared to an adjusted net loss of $5.8 million, or $1.75 per basic and diluted common share, for the same period in 2013. The increased adjusted net loss for the 2014 period was primarily due to an increase in research and development expense of $0.3 million and an increase in general and administrative expense of $0.4 million.
For the six months ended June 30, 2014, the Company reported an adjusted net loss of $12.7 million, or $0.72 per basic and diluted common share, compared with an adjusted net loss of $11.4 million, or $3.74 per basic and diluted common share, for the same period in 2013. The increased adjusted net loss for the 2014 period was primarily due to increases in interest expense of $0.5 million, in research and development expense of $0.5 million and in general and administrative expense of $0.3 million.
The increase in research and development expense for the quarter and six months ended June 30, 2014 was primarily due to an increase in compensation and related expenses resulting from additional employees and an increased use of clinical and regulatory consultants, as well as an increase in external services related to the clinical trials for the Neo-Kidney Augment program. The increase in general and administrative expense for the quarter and six months ended June 30, 2014 was primarily due to an increase in legal fees and professional services related to the preparation of a market assessment of the Neo-Kidney Augment program.The increase in interest expense for the six months ended June 30, 2014 was primarily due to non-cash interest expense associated with the 2012 Convertible Notes issued in the fourth quarter of 2012 and the 2013 Convertible Notes issued in the second quarter of 2013.
As of June 30, 2014, the Company held $10.1 million in cash and cash equivalents. Based on the Company's current expected operating expenditures and debt repayment, and assuming it is not required to settle any outstanding warrants in cash or redeem, or pay cash interest on, any of its convertible notes, the Company expects to be able to fund its operations through December 31, 2014.
About the Neo-Kidney Augment™
The Neo-Kidney Augment is being developed to prevent or delay the need for dialysis by increasing renal function in patients with advanced chronic kidney disease. The Neo-Kidney Augment cellular therapy consists of selected regenerative renal cells obtained from a cortical biopsy of the patient's kidney, expanded ex vivo, and then formulated in a thermolabile gelatin for laparoscopic injection into the patient's kidney by a multi-ported needle, which allows the Neo-Kidney Augment cells to diffuse throughout the kidney and catalyze regeneration of functional kidney tissue.
About the Neo-Urinary Conduit™
The Neo-Urinary Conduit is designed to replace the standard of care for bladder cancer patients undergoing cystectomy (removal of bladder). There are over 25,000 cystectomies performed annually in bladder cancer patients in the United States and Europe. The Neo-Urinary Conduit is an implant made from a patient's own cells and is intended to catalyze regeneration of native-like urinary tissue, thereby eliminating the need to use bowel tissue in the current standard of care surgery.
About Tengion (TNGN)
Tengion (TNGN), a clinical-stage regenerative medicine company, is focused on developing its Organ Regeneration Platform™ to harness the intrinsic regenerative pathways of the body to regenerate a range of native-like organs and tissues with the goal of delaying or eliminating the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications. The Company is currently conducting Phase 1 clinical trials in Sweden and the United States for its Neo-Kidney Augment cellular therapy, which is intended to prevent or delay dialysis and transplantation by increasing renal function in patients with advanced chronic kidney disease. A Phase 1 trial for the Company's Neo-Urinary Conduit, an autologous implant that is intended to catalyze regeneration of native-like urinary tissue for bladder cancer patients requiring a urinary diversion following bladder removal, has completed enrollment.
Not an epic day here:) I'd wager due to no news no news
just grabbed a starter position here. - hoping today doesn't continue tomorrow....
The company has been issuing shares and raised the A/S to an insane 10 Billion (yes, that is TEN BILLION) – this has sub-penny in the next 12 months written all over it…
This stock PPS reminds me of a song, "there's a hole in the bucket....
Looking forward to seeing the release of the Neokidney Augment 6 month data. Should be fascinating, hopefully positive! Should be released in July per SEC filing and Annual Stockholder Meeting.
Some know whats coming to Regenerative Medicine Sector soon. I've got my tickets and all buckled in. I believe, now is not the time to be on the "sidelines", Tony Atala and his friend Bob will guide the ships forward, imo. Amazing how quiet this board has been, as of late? Those wonderful women (patients) and their new vaginas are a testament to the changes upon us. We shall see many a great things in this sector soon, mark this post. GLTA, Go TNGN
We have had a "stealth" buyer in the wings here for a couple of weeks now. Notice the 100K bid size now. This is the typical approach to trying to buy a low volume stock like this: just sit on the bid and hope we get bored and sell.
If said news is tngn specific, yes, lookout. But industry 'general' news I don't see spiking tngn...it must pertain to tngn to move the needle...
BIG News coming to the regenerative medicine sector soon. Don't be left out...the rising tide will raise a lot of ships...imo!
Go TNGN, Thank you Tony Atala !
Latest release tells us they are going full bore on the most lucrative path-kidney, and that trial is going perfectly. Potential revenue in billions on that but a couple years away. Funding good until December. Freezing urinary due to cash restraints despite positive results...
I still own some shares here Company posted Q1 2014 today:
http://www.otcmarkets.com/stock/TNGN/news
Sounds good. This should give us some much-needed publicity.
Stem Cell Summit 2014:
Thursday - April 24, 2014
Tissue Engineering 3:45p
Joydeep Basu, Director, Process Research & Translation, Tengion
Michael West, Founder & Chief Executive Officer, BioTime
Daniel Nolan, Director of Research, Angiocrine Bioscience
[Oral Presentations from Exemplary Submitted Abstracts]
Stem Cell Summit 2014
If that's the case, interesting to see if über quiet pr team makes some noise. From pr perspective, and saying this with winked eye, given the grown organ, could get major pr traction in all sorts of channels if done right...
My understanding is TNGN owns the patent for the matrix and the cell growth. So I would assume these trials would fall under our patents.
Followers
|
32
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
594
|
Created
|
01/19/11
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |